(S (NP (NNS Studies)) (VP (VBP estimate) (SBAR (IN that) (S (NP (EX there)) (VP (MD will) (VP (VB be) (NP (NP (CD 266,120) (JJ new) (NNS cases)) (PP (IN of) (NP (NP (JJ invasive) (ADJP (NP (NML (NML (NN breast) (NN cancer)) (CC and) (NML (CD 40,920) (NN breast))) (NN cancer)) (VBN induced)) (NNS deaths)) (PP (IN in) (NP (NP (DT the) (NN year)) (PP (IN of) (NP (CD 2018) (RB alone))))))))))))) (. .))
(S (PP (IN Despite) (NP (NP (DT the) (NN pervasiveness)) (PP (IN of) (NP (DT this) (NN affliction))))) (, ,) (NP (DT the) (JJ current) (NN process) (S (VP (TO to) (VP (VB obtain) (NP (DT an) (JJ accurate) (NML (NN breast) (NN cancer)) (NN prognosis)))))) (VP (VBZ is) (ADJP (ADJP (JJ tedious)) (CC and) (ADJP (NN time) (VBG consuming))) (, ,) (S (VP (VBG requiring) (NP (DT a) (VBN trained) (NN pathologist)) (S (VP (TO to) (ADVP (RB manually)) (VP (VB examine) (NP (JJ histopathological) (NNS images)) (PP (IN in) (NP (NN order) (S (VP (TO to) (VP (VB identify) (NP (NP (DT the) (NNS features)) (SBAR (WHNP (WDT that)) (S (VP (VBP characterize) (NP (JJ various) (NML (NN cancer) (NN severity)) (NNS levels))))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (NNP MITOS) (HYPH -) (NNP RCNN)) (: :) (NP (NP (DT a) (ADJP (NP (JJ novel) (NN region)) (VBN based)) (JJ convolutional) (JJ neural) (NN network) (PRN (-LRB- -LRB-) (NP (NN RCNN)) (-RRB- -RRB-))) (VP (VBN geared) (PP (IN for) (NP (JJ small) (NN object) (NN detection))) (PP (IN to) (NP (NP (ADVP (RB accurately)) (NP (NN grade) (CD one)) (PP (IN of) (NP (DT the) (CD three) (NNS factors)))) (SBAR (WHNP (WDT that)) (S (VP (VBP characterize) (NP (NP (NP (NN tumor) (NN belligerence)) (VP (VBN described) (PP (IN by) (NP (DT the) (NNP Nottingham) (NNP Grading) (NNP System))))) (: :) (NP (JJ mitotic) (NN count)))))))))))) (. .))
(S (NP (NP (JJ Other) (JJ computational) (NNS approaches)) (PP (IN to) (NP (JJ mitotic) (NN figure) (NN counting) (CC and) (NN detection)))) (VP (VBP do) (RB not) (VP (VB demonstrate) (NP (JJ ample) (NN recall) (CC or) (NN precision)) (S (VP (TO to) (VP (VB be) (ADJP (RB clinically) (JJ viable))))))) (. .))
(S (NP (PRP$ Our) (NNS models)) (VP (VBD outperformed) (NP (DT all) (JJ previous) (NNS participants)) (PP (IN in) (NP (NP (DT the) (NNP ICPR) (CD 2012) (NN challenge)) (, ,) (NP (DT the) (NNP AMIDA) (CD 2013) (NN challenge)) (CC and) (NP (DT the) (NML (NNP MITOS) (HYPH -) (NNP ATYPIA) (HYPH -) (CD 14)) (NN challenge)))) (PP (IN along) (IN with) (NP (ADJP (RB recently) (VBN published)) (NNS works)))) (. .))
(S (NP (PRP$ Our) (NN model)) (VP (VBD achieved) (NP (NP (DT an) (NML (NN F) (HYPH -) (NN measure)) (NN score)) (PP (IN of) (NP (NP (CD 0.955)) (, ,) (NP (NP (DT a) (NML (CD 6.11) (NN %)) (NN improvement)) (PP (IN in) (NP (NN accuracy))))))) (PP (IN from) (NP (NP (DT the) (ADJP (RBS most) (JJ accurate))) (PP (IN of) (NP (DT the) (ADJP (RB previously) (VBN proposed)) (NNS models)))))) (. .))
